Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
AVXL Anavex Life Sciences Corp
- Stocks
- Healthcare
- NASDAQ: AVXL
Price (delayed)
$8.32
Market cap
$710.29M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.55
Enterprise value
$594.52M
Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease,
Highlights
AVXL's quick ratio has shrunk by 54% YoY and by 28% QoQ
Anavex Life Sciences's equity has decreased by 26% YoY and by 10% QoQ
Key stats
What are the main financial stats of AVXL
Market
Valuations
Earnings
Shares outstanding
85.37M
Market cap
$710.29M
Enterprise value
$594.52M
Price to earnings (P/E)
N/A
Price to book (P/B)
7.09
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$55.17M
Net income
-$47.14M
EBIT
-$47.33M
EBITDA
-$47.33M
Free cash flow
-$29.81M
Per share
Balance sheet
Liquidity
EPS
-$0.55
EPS diluted
-$0.55
Free cash flow per share
-$0.35
Book value per share
$1.17
Revenue per share
$0
TBVPS
$1.38
Total assets
$117.14M
Total liabilities
$17.38M
Debt
$0
Equity
$99.76M
Working capital
$99.76M
Debt to equity
0
Current ratio
6.74
Quick ratio
6.66
Net debt/EBITDA
2.45
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-36.4%
Return on equity
-40.9%
Return on invested capital
N/A
Return on capital employed
-47.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AVXL stock price
How has the Anavex Life Sciences stock price performed over time
Intraday
-0.6%
1 week
0.85%
1 month
-5.88%
1 year
84.89%
YTD
-22.53%
QTD
-3.03%
Financial performance
How have Anavex Life Sciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$55.17M
Net income
-$47.14M
Gross margin
N/A
Net margin
N/A
Anavex Life Sciences's net income has decreased by 16% YoY
AVXL's operating income is down by 10% year-on-year
Price vs fundamentals
How does AVXL's price correlate with its fundamentals
Growth
What is Anavex Life Sciences's growth rate over time
Valuation
What is Anavex Life Sciences stock price valuation
P/E
N/A
P/B
7.09
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 8% YoY
The stock's price to book (P/B) is 27% more than its last 4 quarters average of 5.6 and 2.8% more than its 5-year quarterly average of 6.9
Anavex Life Sciences's equity has decreased by 26% YoY and by 10% QoQ
Efficiency
How efficient is Anavex Life Sciences business performance
The ROE has contracted by 41% YoY and by 9% from the previous quarter
AVXL's return on assets is down by 36% year-on-year and by 7% since the previous quarter
Dividends
What is AVXL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AVXL.
Financial health
How did Anavex Life Sciences financials performed over time
Anavex Life Sciences's total liabilities has soared by 82% YoY and by 32% from the previous quarter
The company's current ratio has shrunk by 55% YoY and by 29% QoQ
The debt is 100% smaller than the equity
Anavex Life Sciences's equity has decreased by 26% YoY and by 10% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.